Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restasis for Prevention of Ocular GVHD
NCT00755040Phase 3Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Oct 2008
- Primary completion
- Dec 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine ophthalmic solution in ocular graft-versus-host disease (oGVHD), sponsored by Vanderbilt-Ingram Cancer Center. Started Oct 2008; status: completed.
02
Drugs
cyclosporine ophthalmic solution
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT00755040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00755040.